GLYXAMBI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GLYXAMBI (GLYXAMBI).
GLYXAMBI is a combination of empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin increases incretin hormones (GLP-1, GIP), enhancing insulin release and decreasing glucagon levels in a glucose-dependent manner.
| Metabolism | Empagliflozin is primarily metabolized via glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9. Linagliptin is primarily metabolized via enterohepatic circulation and is eliminated unchanged; minor metabolism via CYP3A4. |
| Excretion | Empagliflozin: Approximately 95.6% excreted in feces (41.2% as unchanged drug) and 54.4% in urine (19.8% as unchanged). Linagliptin: 84% excreted in feces via enterohepatic circulation (80% as parent drug) and 5% in urine. |
| Half-life | Empagliflozin: Terminal half-life ~12.4 hours allows once-daily dosing. Linagliptin: Terminal half-life >100 hours, but pharmacodynamic effect correlates with DPP-4 inhibition rather than plasma levels. |
| Protein binding | Empagliflozin: 86.2% bound to plasma proteins. Linagliptin: 75-89% bound to plasma proteins (concentration-dependent). |
| Volume of Distribution | Empagliflozin: Apparent Vd ~10.6 L (0.15 L/kg) indicates extensive tissue distribution. Linagliptin: Vd ~1,110 L (17.7 L/kg) suggests extensive extravascular distribution. |
| Bioavailability | Empagliflozin: Absolute oral bioavailability 78%. Linagliptin: Absolute oral bioavailability approximately 30%. |
| Onset of Action | Oral: Empagliflozin onset of urinary glucose excretion within 24 hours; linagliptin DPP-4 inhibition begins within 1-2 hours, peak inhibition at 4 hours. |
| Duration of Action | Empagliflozin: Urinary glucose excretion persists for 24 hours enabling once-daily dosing. Linagliptin: DPP-4 inhibition >80% at 24 hours after repeated doses, supporting once-daily administration. |
| Brand Substitutes | Tiptengio 25mg/5mg Tablet, Ajaduo 25mg/5mg Tablet, Xilingio 25mg/5mg Tablet, Tiptengio 10mg/5mg Tablet, Ajaduo 10mg/5mg Tablet, Xilingio 10mg/5mg Tablet |
10 mg/5 mg orally once daily (empagliflozin/linagliptin). May increase to 25 mg/5 mg once daily if tolerated.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥45 mL/min/1.73 m²: no adjustment. eGFR 30-44: use is not recommended due to lack of efficacy data. eGFR <30: contraindicated. |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients; no recommended dose. |
| Geriatric use | No dose adjustment based on age alone. Monitor renal function; avoid use if eGFR <45 mL/min/1.73 m². Elderly patients may be at higher risk for volume depletion and hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GLYXAMBI (GLYXAMBI).
| Breastfeeding | No data on presence in human milk. Empagliflozin is excreted in rat milk; linagliptin is excreted in rat milk. M/P ratio not known. Consider risks to infant; avoid breastfeeding while taking GLYXAMBI. |
| Teratogenic Risk | GLYXAMBI contains empagliflozin and linagliptin. Empagliflozin is not recommended during the second and third trimesters due to potential risk of fetal renal impairment based on animal studies showing renal maturation effects. Linagliptin has no adequate human data; animal studies show no teratogenicity. First trimester risk cannot be excluded. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Type 1 diabetes mellitus","History of diabetic ketoacidosis","Severe renal impairment (eGFR <30 mL/min/1.73 m2) or ESRD","History of hypersensitivity reaction to empagliflozin, linagliptin, or any component","Lactation (no data for combination)"]
| Precautions | ["Pancreatitis (linagliptin)","Heart failure (linagliptin)","Ketoacidosis (empagliflozin)","Acute kidney injury (empagliflozin)","Volume depletion (empagliflozin)","Urosepsis and pyelonephritis (empagliflozin)","Hypoglycemia when used with insulin or insulin secretagogues","Necrotizing fasciitis of the perineum (Fournier's gangrene; empagliflozin)","Bullous pemphigoid (linagliptin)"] |
| Food/Dietary | No significant food interactions. Avoid excessive alcohol intake as it may increase risk of ketoacidosis. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose, renal function, and volume status. For fetus, consider ultrasound for renal development if exposed during second/third trimester. |
| Fertility Effects | Empagliflozin: No adverse effects on fertility in animal studies. Linagliptin: No adverse effects on fertility in animal studies. Human data lacking. |
| Clinical Pearls | Empagliflozin component may cause euglycemic ketoacidosis; check ketones even if glucose normal. Linagliptin component does not require dose adjustment in renal impairment. Monitor volume status in elderly or loop diuretic users. Pancreatitis risk with DPP-4 inhibitors; discontinue if suspected. |
| Patient Advice | Take once daily with or without food. · Stay hydrated to prevent dehydration and hypotension. · Report symptoms of ketoacidosis (nausea, vomiting, abdominal pain, confusion) even if blood sugar is normal. · Seek medical attention for severe joint pain, blistering skin lesions, or signs of pancreatitis. · Inform healthcare provider about all medications, especially diuretics and insulin. · Monitor blood glucose regularly. |